Tevogen Bio Holdings (TVGN) | Financial Analysis & Statements
Tevogen Bio Holdings Inc. Micro-cap Healthcare
TL;DR: Financial Overview - Revenue, Profits & Key Metrics
Latest Quarterly: Dec 2025Income Metrics
Revenue
0
Operating Income
-4.6M
Net Income
-4.7M
Balance Sheet Metrics
Total Assets
4.4M
Total Liabilities
12.6M
Shareholders Equity
-8.2M
Cash Flow Metrics
Operating Cash Flow
-2.6M
Free Cash Flow
-2.2M
Revenue & Profitability Trend
Tevogen Bio Holdings Income Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Goods Sold | - | - | - | - | - |
| Gross Profit | - | - | - | - | - |
| Gross Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Operating Expenses | |||||
| Research & Development | 11.1M | 31.0M | - | 5.8M | 3.0M |
| Selling, General & Administrative | 15.0M | 22.5M | 2.3M | 953.1K | 1.7M |
| Other Operating Expenses | - | - | - | - | - |
| Total Operating Expenses | 26.1M | 53.6M | 2.3M | 6.7M | 4.6M |
| Operating Income | -26.1M | -53.6M | -2.3M | -953.1K | -4.6M |
| Operating Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Non-Operating Items | |||||
| Interest Income | - | - | - | - | - |
| Interest Expense | 195.6K | 184.0K | 256.0K | 0 | 598.5K |
| Other Non-Operating Income | 60.7K | 40.0M | 2.5M | 5.4M | -10.4M |
| Pre-tax Income | -26.3M | -13.7M | -67.3K | 4.4M | -15.6M |
| Income Tax | - | - | - | - | - |
| Effective Tax Rate % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Net Income | -26.3M | -13.7M | -67.3K | 4.4M | -15.6M |
| Net Margin % | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% |
| Key Metrics | |||||
| EBITDA | -25.6M | -4.7M | -2.3M | -953.1K | -15.0M |
| EPS (Basic) | $-8.08 | $-3.50 | $0.00 | $0.04 | $-0.13 |
| EPS (Diluted) | $-8.08 | $-3.50 | $0.00 | $0.04 | $-0.13 |
| Basic Shares Outstanding | 3319812 | 2933450 | 165421084 | 119999989 | 119999989 |
| Diluted Shares Outstanding | 3319812 | 2933450 | 165421084 | 119999989 | 119999989 |
Income Statement Trend
Join Our United States Telegram Channel
Get Instant Market Updates: 52-Week High/Low Alerts, Breakout Notifications & Expert Stock Analysis Delivered To Your Phone. Join Traders Making Informed Decisions Daily!
Tevogen Bio Holdings Balance Sheet From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Assets | |||||
| Current Assets | |||||
| Cash & Equivalents | 552.4K | 1.3M | 8.8K | 129.2K | 7.1M |
| Short-term Investments | - | - | - | - | - |
| Accounts Receivable | - | - | - | - | - |
| Inventory | - | - | - | - | - |
| Other Current Assets | 828.6K | 919.1K | 2.5K | 145.2K | 54.0K |
| Total Current Assets | 1.5M | 2.4M | 355.8K | 274.4K | 7.2M |
| Non-Current Assets | |||||
| Property, Plant & Equipment | 1.4M | 228.5K | - | 684.9K | 0 |
| Goodwill | - | - | - | - | - |
| Intangible Assets | - | - | - | - | - |
| Long-term Investments | - | - | - | - | - |
| Other Non-Current Assets | 1.2M | 575.8K | 16.7M | 356.9M | 342.6K |
| Total Non-Current Assets | 2.8M | 1.1M | 16.7M | 356.9M | 485.3K |
| Total Assets | 4.4M | 3.5M | 17.0M | 357.1M | 7.7M |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts Payable | 3.3M | 5.2M | 1.1M | 210.5K | 378.0K |
| Short-term Debt | 2.0M | 1.9M | 1.6M | 278.2K | - |
| Current Portion of Long-term Debt | - | - | - | - | - |
| Other Current Liabilities | 331.1K | 403.2K | - | 237.6K | 45.3K |
| Total Current Liabilities | 7.1M | 9.0M | 3.0M | 350.5K | 667.9K |
| Non-Current Liabilities | |||||
| Long-term Debt | 5.5M | 1.0M | - | 39.7M | 23.5M |
| Deferred Tax Liabilities | - | - | - | - | - |
| Other Non-Current Liabilities | - | - | - | - | - |
| Total Non-Current Liabilities | 5.5M | 1.1M | 14.7M | 14.7M | 23.5M |
| Total Liabilities | 12.6M | 10.1M | 17.7M | 15.1M | 24.1M |
| Equity | |||||
| Common Stock | 402 | 17.8K | 16.7M | 356.9M | 63.9K |
| Retained Earnings | -139.7M | -113.4M | -17.4M | -14.8M | -17.1M |
| Treasury Stock | - | - | - | - | - |
| Other Equity | - | - | - | - | - |
| Total Shareholders Equity | -8.2M | -6.7M | -695.8K | 342.1M | -16.5M |
| Key Metrics | |||||
| Total Debt | 7.5M | 2.9M | 1.6M | 40.0M | 23.5M |
| Working Capital | -5.5M | -6.7M | -2.6M | -76.1K | 6.5M |
Balance Sheet Composition
Tevogen Bio Holdings Cash Flow Statement From 2021 to 2025
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Operating Activities | |||||
| Net Income | -26.3M | -13.7M | -67.3K | 4.4M | -15.6M |
| Depreciation & Amortization | 509.2K | 403.6K | - | 230.8K | 9.4K |
| Stock-Based Compensation | 16.2M | 40.8M | - | 4.6M | 582.4K |
| Working Capital Changes | -2.8M | 922.0K | 665.0K | -195.5K | -1.4M |
| Operating Cash Flow | -12.3M | -11.1M | 853.7K | 17.3M | -5.5M |
| Investing Activities | |||||
| Capital Expenditures | -64.4K | 0 | - | -479.0K | -109.7K |
| Acquisitions | - | - | - | - | - |
| Investment Purchases | - | - | - | - | - |
| Investment Sales | - | - | - | - | - |
| Investing Cash Flow | -64.4K | 0 | 342.9M | -479.0K | -109.7K |
| Financing Activities | |||||
| Share Repurchases | - | - | -343.0M | 0 | - |
| Dividends Paid | - | - | - | - | - |
| Debt Issuance | 3.4M | 1.0M | - | 7.5M | 12.5M |
| Debt Repayment | - | - | - | - | - |
| Financing Cash Flow | 11.7M | 12.2M | -341.7M | 7.5M | 12.5M |
| Free Cash Flow | -12.4M | -12.0M | -1.4M | -215.4K | -5.4M |
| Net Change in Cash | -697.6K | 1.1M | 2.1M | 24.4M | 6.9M |
Cash Flow Trend
Tevogen Bio Holdings Key Financial Ratios
Valuation Ratios
P/E Ratio (TTM)
2.86
Forward P/E
-0.54
Profitability Ratios
Profit Margin
0.00%
Operating Margin
0.00%
Return on Equity
319.08%
Return on Assets
-416.53%
Financial Health
Current Ratio
0.22
Debt to Equity
-0.91
Beta
-0.30
Per Share Data
EPS (TTM)
$-8.08
Book Value per Share
$-2.12
Revenue per Share
$0.00
Peer Financial Comparison
| Company | Market Cap | P/E Ratio | P/B Ratio | ROE | Profit Margin | Debt/Equity |
|---|---|---|---|---|---|---|
| TVGN | 29.2M | 2.86 | - | 319.08% | 0.00% | -0.91 |
| Vertex | 109.4B | 28.40 | 5.92 | 22.54% | 32.94% | 10.91 |
| Regeneron | 81.0B | 18.00 | 2.45 | 14.86% | 31.41% | 9.51 |
| Adagene | 243.8M | - | 4.95 | -34.39% | -229.56% | 12.07 |
| Orchestra BioMed | 242.9M | - | 4.48 | -109.41% | -157.40% | 25.17 |
| Third Harmonic Bio | 242.8M | 12.46 | 0.89 | -19.94% | 0.00% | 1.10 |
Financial data is updated regularly. All figures are in the company's reporting currency.






